Physician

Adam Burgoyne, M.D., PH.D.

According to 2025 Medicare claims, Adam Burgoyne, M.D., PH.D. (NPI: 1356638969) practices hematology/oncology in the San Diego-Chula Vista-Carlsbad, CA market, with the plurality of this provider's patient population coming from San Diego, CA. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1508968751; TIN: 237064656) and primary practice location at 92093-1503.

Burgoyne's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 95 traditional Medicare patients, billed 843 HCPCS/CPT codes, and received $57,334 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 504 prescription claims across 81 beneficiaries totaling $1,351,027 in drug costs, led by Lenvima (Lenvatinib Mesylate). 2023 DME data shows 11 claims. Open Payments data shows 94 records totaling $1,351,233. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $9,596 to $57,334. Similarly, Part D prescription costs have moved sharply higher in recent years, from $59,472 to $1,351,027. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	27	106	$9,596
2018	55	210	$18,084
2019	80	340	$31,449
2020	84	418	$36,748
2021	70	320	$36,462
2022	83	324	$37,050
2023	87	405	$45,326
2024	95	843	$57,334

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	14	69	$59,472
2018	22	106	$283,900
2019	34	239	$326,871
2020	42	402	$834,440
2021	46	346	$1,242,686
2022	42	347	$1,277,877
2023	61	361	$996,722
2024	81	504	$1,351,027

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	16	$3,389
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	11	$207
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	27	27	$147
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	72	361	$118
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	15	23	$79
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	89	399	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenvima	Lenvatinib Mesylate	37	1,110	$820,981
Sunitinib Malate	Sunitinib Malate	18	616	$132,228
Imatinib Mesylate	Imatinib Mesylate	53	1,800	$41,412
Eliquis	Apixaban	12	780	$14,816
Olanzapine	Olanzapine	32	1,020	$615

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	45	$46,075	Boston Scientific Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	49	$1,305,159	Genentech, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Burgoyne, M.D., PH.D.?

Tedicare shows public-source Medicare data for Adam Burgoyne, M.D., PH.D. (NPI 1356638969), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Burgoyne, M.D., PH.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Burgoyne, M.D., PH.D.?

Adam Burgoyne, M.D., PH.D. is linked to REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1508968751) in the available physician profile data.

Does Adam Burgoyne, M.D., PH.D. have Open Payments data?

Adam Burgoyne, M.D., PH.D. has 94 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.